The free radical theory of aging postulates that free radicals are the underlying cause of aging. One of the well-established age-associated disorders is the decrease in the insulin-stimulated glucose transport through the cell membrane which was reported to be a major mechanism underlying insulin resistance in old rats. The present study investigates the protective capacity of two known antioxidants, vitamin C and butylated hydroxytoluene (BHT), against age-associated free radical damage, which could be the reason behind the decreased insulin-stimulated glucose transport in old animals. Maximum insulin-stimulated glucose transport has been estimated in adipocytes isolated from adult 6-month-old Fischer rats and from senile 24-month-old control rats as well as from 24-month-old rats that were fed either vitamin C or BHT for 18 months. A significant increase in maximum insulin-stimulated glucose transport was observed in the BHT (p = 0.015) and the vitamin C groups (p = 0.039) compared with the control group of the same age. Significant stimulations with insulin over basal activities were also observed in the BHT group (p = 0.0001) as well as the vitamin C group (p = 0.009), while a nonsignificant stimulation (p = 0.097) was observed in the old control group. This study suggests a protective role that BHT (fat soluble) may have on the lipid moiety of the cell membrane and vitamin C (water soluble) on one or more of the intracellular cytoplasmic constituents concerned with glucose transport.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000213699 | DOI Listing |
Ann Pharmacother
January 2025
Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Objective: There is limited knowledge about severe urinary tract infections associated with SGLT2i, despite this being the basis for the Food and Drug Administration (FDA) warning. We aim to provide real-world evidence to clarify this relationship further.
Data Source: A literature review was performed in PubMed and Embase for cohort studies published up to August 2024 using PICO-consistent terms.
Nat Rev Nephrol
January 2025
New York University Grossman School of Medicine, New York, NY, USA.
The timely and rational institution of therapy is a key step towards reducing the global burden of chronic kidney disease (CKD). CKD is a heterogeneous entity with varied aetiologies and diverse trajectories, which include risk of kidney failure but also cardiovascular events and death. Developments in the past decade include substantial progress in CKD risk prediction, driven in part by the accumulation of electronic health records data.
View Article and Find Full Text PDFNat Rev Dis Primers
January 2025
Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians University, Munich, Germany.
Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney function or structure that have consequences for the health. A progressive decline of excretory kidney function has effects on body homeostasis. CKD is tightly associated with accelerated cardiovascular disease and severe infections, and with premature death.
View Article and Find Full Text PDFFood Chem
January 2025
Xiamen Medical College, Xiamen, Fujian 361023, China. Electronic address:
This study analyzed dipeptidyl peptidase-IV (DPP-IV) inhibitory peptides from Tartary buckwheat (Fagopyrum tataricum) protein hydrolysates, known for managing chronic diseases. Simulated gastrointestinal digestion enhanced the inhibitory activity of DPP-IV. Using anion-exchange resin DEAE-52, reverse high-performance liquid chromatography, and LC-MS/MS, eight novel peptides were identified.
View Article and Find Full Text PDFDiabetes Ther
January 2025
The State Key Laboratory Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.
Introduction: Scientific publications have shown sodium-glucose co-transporter-2 (SGLT2) inhibitors to have several beneficial effects in patients with complex type 2 diabetes mellitus (T2DM). However, sodium-glucose co-transporter-1 (SGLT-1) inhibitor is still under investigation in clinical trials. Recently, a dual inhibitor of sodium-glucose co-transporter (SGLT1/2), sotagliflozin, has been approved for use in patients with T2DM.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!